World Class. Our People. Our Science. Our Therapies. Press Releases ReViral Announces Positive Recommendation by the Data Safety Monitoring Committee to Continue the Phase 2 Clinical Study of Sisunatovir for Treatment of Respiratory Syncytial Virus Infections in Hospitalized Infants Jun 16, 2021 by ReViral Ltd Read More ReViral and LianBio Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Sisunatovir in China Mar 2, 2021 by ReViral Ltd Read More ReViral Raises $44 Million in Series C Financing Aug 25, 2020 by ReViral Ltd Read More ReViral Announces FDA Fast Track Designation Granted to Sisunatovir For The Treatment of Serious Respiratory Syncytial Virus Infection Aug 4, 2020 by ReViral Ltd Read More Impact of RSV highlighted on BBC Radio 4’s ‘Inside Health’ Programme Feb 4, 2020 by ReViral Ltd Read More Archives Archives Select Year 2021 2020 2019 2018 2017 2016 2015 2014 2013 View All
ReViral Announces Positive Recommendation by the Data Safety Monitoring Committee to Continue the Phase 2 Clinical Study of Sisunatovir for Treatment of Respiratory Syncytial Virus Infections in Hospitalized Infants Jun 16, 2021 by ReViral Ltd Read More
ReViral and LianBio Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Sisunatovir in China Mar 2, 2021 by ReViral Ltd Read More
ReViral Announces FDA Fast Track Designation Granted to Sisunatovir For The Treatment of Serious Respiratory Syncytial Virus Infection Aug 4, 2020 by ReViral Ltd Read More
Impact of RSV highlighted on BBC Radio 4’s ‘Inside Health’ Programme Feb 4, 2020 by ReViral Ltd Read More
